Standout Papers

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Advers... 2015 2026 2018 2022 626
  1. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes (2015)
    Morganna Freeman-Keller, Young‐Chul Kim et al. Clinical Cancer Research

Immediate Impact

2 by Nobel laureates 6 from Science/Nature 68 standout
Sub-graph 1 of 20

Citing Papers

Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
2024 Standout
A high-fat diet promotes cancer progression by inducing gut microbiota–mediated leucine production and PMN-MDSC differentiation
2024 Standout
1 intermediate paper

Works of Heather Cronin being referenced

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
2016

Author Peers

Author Last Decade Papers Cites
Heather Cronin 73 171 10 723 285 15 1.1k
David Hamm 55 161 2 294 667 35 1.2k
Winnie Lau 101 274 78 100 231 33 1.3k
Anne L Langston 95 207 1 477 248 23 1.1k
Rumela Chakrabarti 78 588 7 438 175 27 1.0k
Peiming Ma 78 342 23 409 193 31 1.2k
IL Weissman 23 466 3 242 476 13 1.2k
P. De Angelis 272 429 6 318 127 36 1.2k
Cristina López 191 265 5 140 167 43 880
Andrew F. Giusti 38 241 2 200 53 14 989
Hiroshi Sasaki 36 436 9 361 57 44 1.3k

All Works

Loading papers...

Rankless by CCL
2026